Investigators selected participants from a prospective Michigan cohort who had received five or more COVID-19 vaccine doses between 2020 and 2025. The report included 21 participants. Median vaccine count in the sample was seven doses. The manuscript states participants had complex immune histories that included multiple vaccinations and infections during the Omicron period. The authors did not report additional participant-level demographics in the abstract; full details may be in the supplementary material or the full text.
The study team measured serum IgG, IgM, and ACE2 percent inhibition using multiplex assays. Regression models were used to evaluate baseline-adjusted immunogenicity, cross-reactivity across strains, and formulation-specific antibody durability. The report specifies comparisons across monovalent, bivalent, and 2023–24 vaccine formulations, and examines fold-rise in antibody concentrations relative to pre-vaccination baselines. The exact assay panels, antigen targets, and normalization procedures were not detailed in the abstract; readers should consult the full paper for assay protocols.
Data indicated that higher pre-vaccination IgG was associated with smaller post-vaccination fold-rises. Specifically, for every two-fold increase in baseline IgG, the post-vaccination fold-rise was 34% lower after monovalent vaccination (95% CI: 16%–48%), 43% lower after bivalent vaccination (95% CI: 15%–62%), and 55% lower after 2023–24 vaccination (95% CI: 21%–75%). These numbers came from baseline-adjusted regression analyses reported by the authors. When the team adjusted for baseline levels, overall immunogenicity did not display consistent directional trends across successive vaccine doses, suggesting that repeated boosting continued to reinforce humoral responses even in participants with complex prior exposure.
Antibody landscape visualizations—described in the manuscript—showed broad cross-reactivity to both ancestral and multiple Omicron variants. The study team reported similar strain-specific IgG changes across ancestral strains, vaccine-matched strains, and antigenically distant strains. In contrast, ACE2 percent inhibition showed greater heterogeneity across strains, indicating variability in functional inhibition despite broadly similar binding antibody profiles. The abstract does not provide strain-by-strain numerical values; the full text and supplementary figures likely present detailed antigen-specific titers and inhibition matrices.
The authors modeled antibody waning by vaccine formulation. Significant IgG declines were observed following monovalent vaccination (beta = -1.03; 95% CI: -1.51 to -0.55; P<0.001) and following bivalent vaccination (beta = -1.00; 95% CI: -1.71 to -0.30; P=0.007). The team also reported declines in ACE2 inhibition after monovalent vaccination. Other formulations showed less consistent or non-significant changes in the abstract. The report therefore points to formulation-specific durability differences rather than uniform decay across all vaccine types.
Despite measurable waning for certain formulations, antibody levels generally remained relatively high across variants up to 300 days post-vaccination according to the authors. This persistence applied to binding IgG measures and, variably, to ACE2 inhibition depending on formulation and strain. The abstract notes durable responses but does not specify quantitative titer thresholds or correlate these levels with clinical protection; no clinical effectiveness endpoints were reported in the abstract.
The authors acknowledged that repeated vaccination produced complex immune histories, which may complicate simple comparisons across vaccine doses and formulations. The abstract does not list other detailed limitations such as sample size constraints beyond reporting the cohort of 21 participants; readers should consult the full manuscript for a complete limitations section. The University of Michigan Institutional Review Board provided ethical approval, and informed consent procedures were described. The authors declared no direct conflicts of interest related to this research and disclosed other external activities unrelated to the study. Data are available on request but are controlled by IRB rules and the Centers for Excellence in Influenza Research and Response (CEIRR) Network; interested investigators must complete a data and specimen collaboration form and await review by study investigators.
Remaining questions documented in the abstract include the generalizability of findings beyond the sampled participants and the detailed antigen-specific quantitative results, which are available in the full text and supplementary material. The report is a preprint and has not been peer reviewed; it should not be used to guide clinical practice without further validation.